Home > Cardiology > AHA 2021 > Letter from the Editor

Letter from the Editor

Prof. Marc Bonaca, University of Colorado, USA
AHA 2021
Dear Readers,

Thank you for choosing our Medicom Conference Report of the 2021 American Heart Association Scientific Sessions. This year’s meeting was rich in innovative science, late-breaking studies, and engaging virtual content.

In the following pages, you will find late-breaking science on digital interventions in atrial fibrillation, remote virtual programs for population management of hypertension and hyperlipidemia, exciting data on novel anticoagulants and new evidence in heart failure, vascular disease and coronary disease.

We hope you find our peer-reviewed summaries informative, engaging and balanced. Most of all, we wish you all a safe and healthy 2022 and hope that this year brings our scientific community even closer together.




Marc Bonaca



Marc P. Bonaca, MD, MPH, is a Cardiologist and Vascular Medicine Specialist who serves as the Executive Director of CPC Clinical Research and CPC Community Health at the University of Colorado Anschutz Medical Campus. He is the Director of Vascular Research and an Associate Professor of Medicine at the University of Colorado School of Medicine and the inaugural holder of the William R. Hiatt Endowed Chair in Cardiovascular Research.

Dr Bonaca earned his medical degree from the University of Connecticut School of Medicine and his Masters in Public Health at Harvard University. He served as a Medical House Officer at Brigham and Women’s Hospital and Harvard Medical School. After completion of his training, he joined the faculty of the Cardiovascular Division and Vascular Medicine section of Brigham and Women’s Hospital and Harvard Medical School and became an Investigator at the TIMI Study Group.

Dr Bonaca’s research focus is on ischemic risk in patients with atherosclerotic vascular disease, risk prediction, and risk modification through the use of pharmacologic and biologic therapies. His key areas of interest include patients with peripheral artery disease, polyvascular disease and diabetes with a focus on the breadth of risk including ischemic limb outcomes, microvascular complications and major adverse cardiovascular events.

Conflict of Interest Statement:

Grant support to BWH from AstraZeneca, MedImmune, Merck, PfizerGrant support to CPC from Amgen, AstraZeneca, Bayer, Janssen, NovoNordisk, Sanofi

Posted on